Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients

Autores
Maciel, Olga; Vera, Zully; Marín, Gustavo Horacio; Maidana, Mabel; Samaniego, Lourdes; Lugo, Gladys; Mastroianni, Patricia
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Type 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment’s costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The costeffectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.
Facultad de Ciencias Médicas
Consejo Nacional de Investigaciones Científicas y Técnicas
Materia
Medicina
Cost-effectiveness
Type 2 diabetes
Adherence
Pharmacotherapy compliance
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/99653
Acceder
id SEDICI_e3a2281017e7713265ca2fb497cf1437
oai_identifier_str oai:sedici.unlp.edu.ar:10915/99653
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Cost-effectiveness of drug compliance in type 2 diabetes mellitus patientsMaciel, OlgaVera, ZullyMarín, Gustavo HoracioMaidana, MabelSamaniego, LourdesLugo, GladysMastroianni, PatriciaMedicinaCost-effectivenessType 2 diabetesAdherencePharmacotherapy complianceType 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment’s costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The costeffectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.Facultad de Ciencias MédicasConsejo Nacional de Investigaciones Científicas y Técnicas2018-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf1824-1829http://sedici.unlp.edu.ar/handle/10915/99653enginfo:eu-repo/semantics/altIdentifier/url/https://ri.conicet.gov.ar/11336/84321info:eu-repo/semantics/altIdentifier/url/https://www.rjpbcs.com/pdf/2018_9(5)/[230].pdfinfo:eu-repo/semantics/altIdentifier/issn/0975-8585info:eu-repo/semantics/altIdentifier/hdl/11336/84321info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:12:24Zoai:sedici.unlp.edu.ar:10915/99653Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:12:24.286SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients
title Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients
spellingShingle Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients
Maciel, Olga
Medicina
Cost-effectiveness
Type 2 diabetes
Adherence
Pharmacotherapy compliance
title_short Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients
title_full Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients
title_fullStr Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients
title_full_unstemmed Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients
title_sort Cost-effectiveness of drug compliance in type 2 diabetes mellitus patients
dc.creator.none.fl_str_mv Maciel, Olga
Vera, Zully
Marín, Gustavo Horacio
Maidana, Mabel
Samaniego, Lourdes
Lugo, Gladys
Mastroianni, Patricia
author Maciel, Olga
author_facet Maciel, Olga
Vera, Zully
Marín, Gustavo Horacio
Maidana, Mabel
Samaniego, Lourdes
Lugo, Gladys
Mastroianni, Patricia
author_role author
author2 Vera, Zully
Marín, Gustavo Horacio
Maidana, Mabel
Samaniego, Lourdes
Lugo, Gladys
Mastroianni, Patricia
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Medicina
Cost-effectiveness
Type 2 diabetes
Adherence
Pharmacotherapy compliance
topic Medicina
Cost-effectiveness
Type 2 diabetes
Adherence
Pharmacotherapy compliance
dc.description.none.fl_txt_mv Type 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment’s costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The costeffectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.
Facultad de Ciencias Médicas
Consejo Nacional de Investigaciones Científicas y Técnicas
description Type 2 diabetes mellitus affects 15% of the population around the world, causing health complications and increasing the treatment’s costs. Being a chronic outpatient treatment disease, patient compliance is higher importance to achieve therapeutic success. The present study measure the cost effectiveness of the compliance of this disease. An observational, cross-sectional, pharmaco-economic study was performed. A National program to stimulate treatment adherence was taken as intervention stage. Compliance was measure by Morisky-Green test and details of the events in each patient's health (medication, consultations, hospitalization and concomitant treatments) were used to determinate the direct costs for Ministry of Public Health. Effectiveness was measured by percentage of glycated hemoglobin (HbA1c). The sample obtained was 55 patients, which were grouped into 31 compliant and 24 non-compliant. The costeffectiveness of compliance was 466 US$ / compliant effective patient and 1,807 US$ / non-compliant effective patient. The cost-effectiveness of hypoglycemic drug therapy compliance is significantly lower (almost 4 times) than non-compliance. Type 2 Diabetes Mellitus patients that have no therapy adherence are not able to maintain protective levels of HbA1c. In addition, for the Ministry of Public Health, the lack of adherence requires more budget to accomplished the health goals.
publishDate 2018
dc.date.none.fl_str_mv 2018-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/99653
url http://sedici.unlp.edu.ar/handle/10915/99653
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://ri.conicet.gov.ar/11336/84321
info:eu-repo/semantics/altIdentifier/url/https://www.rjpbcs.com/pdf/2018_9(5)/[230].pdf
info:eu-repo/semantics/altIdentifier/issn/0975-8585
info:eu-repo/semantics/altIdentifier/hdl/11336/84321
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
1824-1829
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1846064181676081152
score 13.22299

Publicaciones similares